New British Medical Study Indicates Daily Resveratrol Reduced Tumor Cell Proliferation in the Colon
A new study released by Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, RKCSB, LRI, University of Leicester, Leicester LE2 7LX, United Kingdom indicate that daily doses of at least 0.5 g resveratrol were enough to produce an anticancer effect, and suggest that the drug may have potential as a chemopreventive agent. Researchers recruited 20 patients with resectable colon cancer who were scheduled to undergo surgical resection into the study. Ten patients were assigned to 0.5 g resveratrol prior for 8 days to resection and 10 were assigned to 1 g.Resveratrol sulfate glucuronide was a prominent metabolite in colorectal tissue of five patients assigned to the 0.5 g dose and nine patients assigned to the 1 g dose.In most cases, researchers said concentrations of resveratrol and its metabolic conjugates were higher in samples taken from the cecum, ascending colon and hepatic flexure/transverse colon compared with concentrations found in the splenic flexure, descending colon, sigmoid colon and rectum.The highest mean concentration of parent resveratrol was 18.9 nmol/g in the 0.5 g group and 674 nmol/g in the 1.0 g group, assuming 1 mL weighs 1 g, in normal tissue localized proximal to the tumor on the right side. In right-sided tumors, the highest mean concentration in the 8.33 nmol/g in the 0.5 g group and 94.1 nmol/g in the 1.0 g group.
Overall, tumor cell Ki-67 staining declined from 88.0% ± 6.64% in predose biopsy samples to 83.2% ± 10.0% in samples taken following surgery. When researchers analyzed the dosing groups separately, resveratrol decreased tumor cell Ki-67 staining by 5.6% in the 0.5 g group and 1.9% in the 1 g group, though the reduction was not considered significant.